Bart J F van den Bemt
Overview
Explore the profile of Bart J F van den Bemt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
1403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haegens L, Huiskes V, van den Bemt B, Bekker C
J Med Internet Res
. 2025 Mar;
27:e57697.
PMID: 40080817
Background: Introduction: Patients with inflammatory rheumatic diseases (IRDs) frequently experience drug-related problems (DRPs). DRPs can have negative health consequences and should be addressed promptly to prevent complications. A digital human,...
2.
van Lint J, Vriezekolk J, Jessurun N, den Broeder A, van den Bemt B, Huiskes V
Rheumatol Int
. 2025 Jan;
45(1):24.
PMID: 39797990
This study investigated severity, course and patterns of fatigue surrounding subcutaneous biological disease-modifying antirheumatic drug (bDMARD) injection in inflammatory rheumatic disease (IRD) patients using ecological momentary assessments and investigated self-reported...
3.
Ellerbroek H, Kalkman G, Kramers C, Schellekens A, van den Bemt B
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768692
: As long-term prescription opioid use is associated with increased morbidity and mortality, timely dose reduction of prescription opioids should be considered. However, most research has been conducted on patients...
4.
Hartog M, van Berkel J, van den Bemt B, van den Ende C, Popa C
Rheumatol Adv Pract
. 2024 Nov;
8(4):rkae136.
PMID: 39588297
Objectives: To explore patient characteristics associated with response to intramuscular methylprednisolone (MP) therapy in hand OA. Methods: We performed an exploratory monocentric retrospective study. Patients with a clinical diagnosis of...
5.
van der Ven J, van den Bemt B, Ariaans F, Vriezekolk J, Flendrie M, Verhoef L
Rheumatol Adv Pract
. 2024 Oct;
8(4):rkae125.
PMID: 39439748
Objectives: To investigate the support needs of patients with gout regarding information, communication, treatment and disease monitoring, and patients' views on and preferences for eHealth applications to address these needs....
6.
van der Ven J, van den Bemt B, Flendrie M, Vriezekolk J, Verhoef L
Arthritis Care Res (Hoboken)
. 2024 Oct;
PMID: 39420572
Objective: This study aimed to identify modifiable determinants of self-management behavior in patients with gout. Methods: Four databases (Medline, Embase, PsycINFO, and CINAHL) were searched using terms related to gout,...
7.
Smale E, Ottenbros A, van den Bemt B, Heerdink E, Verploegen J, van Zelm R, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2438677.
PMID: 39388180
Importance: Medications are associated with substantial environmental outcomes, yet frequently end up being unused by patients. Waste-minimizing interventions, such as redispensing of quality-approved oral anticancer drugs remaining unused by patients...
8.
Gebregeorgise D, Gedif Fenta T, van den Bemt B, Bekker C
BMC Public Health
. 2024 Sep;
24(1):2527.
PMID: 39289699
Background: Medication waste poses health, economic, and environmental challenges. However, the extent among patients living in rural areas is underexplored. This study assessed the proportion of prescribed medications remaining unused...
9.
Smale E, Verkerk E, Heerdink E, Egberts T, van den Bemt B, Bekker C
Explor Res Clin Soc Pharm
. 2024 Sep;
15:100493.
PMID: 39263193
Background: Minimizing medication waste through the redispensing of oral anticancer drugs (OADs) that were unused by patients provides economic and environmental benefits, but this is not yet universally implemented in...
10.
van de Steeg B, Esselink A, de Wit H, Kramers C, van den Bemt B
Patient Prefer Adherence
. 2024 Aug;
18:1779-1788.
PMID: 39192874
Purpose: Arterial and venous thromboembolism are a leading cause of mortality. Direct oral anticoagulants (DOACs) are highly effective in both stroke prevention and prevention of venous thrombotic events. Medication adherence...